Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Stock analysts at Wedbush lowered their Q3 2016 earnings per share estimates for shares of Sarepta Therapeutics in a report released on Tuesday. Wedbush analyst H. Behanna now anticipates that the brokerage will earn ($1.41) per share for the quarter, down from their previous forecast of ($1.26). Wedbush has a “Outperform” rating and a $66.00 price objective on the stock. Wedbush also issued estimates for Sarepta Therapeutics’ FY2016 earnings at ($5.24) EPS, Q1 2017 earnings at ($0.79) EPS, Q2 2017 earnings at ($0.84) EPS, Q3 2017 earnings at ($0.77) EPS, Q4 2017 earnings at ($0.83) EPS, FY2017 earnings at ($3.25) EPS, FY2018 earnings at ($2.13) EPS and FY2019 earnings at $0.76 EPS.

Several other equities research analysts also recently issued reports on the company. Cowen and Company restated a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, August 15th. Janney Montgomery Scott upgraded Sarepta Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $30.00 to $65.00 in a report on Monday, September 19th. William Blair restated an “outperform” rating and set a $88.00 price objective on shares of Sarepta Therapeutics in a report on Sunday. Jefferies Group restated an “underperform” rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a report on Saturday, June 25th. Finally, Robert W. Baird restated an “outperform” rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $58.12.

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.917% on Thursday, reaching $62.922. 1,493,678 shares of the company’s stock were exchanged. The company’s market capitalization is $3.01 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73. The company has a 50 day moving average price of $39.01 and a 200-day moving average price of $24.87.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business earned ($0.87) EPS.

In other news, SVP David T. Howton sold 7,000 shares of the company’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $420,000.00. Following the completion of the sale, the senior vice president now owns 28,453 shares in the company, valued at $1,707,180. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David T. Howton sold 9,304 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $465,200.00. Following the completion of the sale, the senior vice president now owns 11,168 shares of the company’s stock, valued at approximately $558,400. The disclosure for this sale can be found here. 10.90% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas raised its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $211,000. BNP Paribas Arbitrage SA increased its stake in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock valued at $217,000 after buying an additional 1,886 shares in the last quarter. Finally, National Planning Corp increased its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.